Glenmede Trust Co. NA reduced its position in Acadia Healthcare Company Inc (NASDAQ:ACHC) by 16.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 988,329 shares of the company’s stock after selling 197,030 shares during the quarter. Glenmede Trust Co. NA owned about 1.13% of Acadia Healthcare worth $32,248,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ACHC. Nationwide Fund Advisors increased its holdings in Acadia Healthcare by 5.2% in the 3rd quarter. Nationwide Fund Advisors now owns 259,773 shares of the company’s stock valued at $12,407,000 after buying an additional 12,931 shares during the period. Crossmark Global Holdings Inc. bought a new position in Acadia Healthcare in the 3rd quarter valued at about $441,000. American Century Companies Inc. increased its holdings in Acadia Healthcare by 6.8% in the 3rd quarter. American Century Companies Inc. now owns 139,878 shares of the company’s stock valued at $6,681,000 after buying an additional 8,937 shares during the period. Principal Financial Group Inc. increased its holdings in Acadia Healthcare by 11.2% in the 3rd quarter. Principal Financial Group Inc. now owns 347,283 shares of the company’s stock valued at $16,586,000 after buying an additional 34,938 shares during the period. Finally, Candriam Luxembourg S.C.A. bought a new position in Acadia Healthcare in the 3rd quarter valued at about $478,000.

How to Become a New Pot Stock Millionaire

Shares of Acadia Healthcare Company Inc (ACHC) opened at $40.79 on Tuesday. The stock has a market cap of $3,620.02, a P/E ratio of 17.81, a P/E/G ratio of 1.34 and a beta of 0.69. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.25. Acadia Healthcare Company Inc has a 1-year low of $26.92 and a 1-year high of $54.34.

Acadia Healthcare (NASDAQ:ACHC) last posted its earnings results on Wednesday, February 21st. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.54 by $0.07. Acadia Healthcare had a net margin of 6.92% and a return on equity of 8.16%. The business had revenue of $724.50 million for the quarter, compared to the consensus estimate of $713.20 million. During the same period last year, the company earned $0.59 EPS. The firm’s revenue was up 3.1% compared to the same quarter last year. research analysts anticipate that Acadia Healthcare Company Inc will post 2.45 earnings per share for the current fiscal year.

In related news, VP Randall P. Goldberg sold 960 shares of Acadia Healthcare stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $38.47, for a total transaction of $36,931.20. Following the sale, the vice president now directly owns 6,942 shares in the company, valued at approximately $267,058.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Reeve B. Waud sold 7,698 shares of Acadia Healthcare stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $42.03, for a total transaction of $323,546.94. Following the sale, the director now owns 10,088 shares in the company, valued at $423,998.64. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 401,360 shares of company stock worth $15,759,096. 11.10% of the stock is owned by corporate insiders.

ACHC has been the topic of several recent analyst reports. BidaskClub lowered shares of Acadia Healthcare from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Robert W. Baird set a $42.00 target price on shares of Acadia Healthcare and gave the company a “hold” rating in a report on Thursday, February 22nd. Jefferies Group set a $42.00 target price on shares of Acadia Healthcare and gave the company a “buy” rating in a report on Tuesday, December 19th. Cantor Fitzgerald raised shares of Acadia Healthcare from a “neutral” rating to an “overweight” rating in a report on Sunday, February 25th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $40.00 price target (up from $35.00) on shares of Acadia Healthcare in a report on Thursday, February 22nd. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $44.50.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.watchlistnews.com/acadia-healthcare-company-inc-achc-holdings-reduced-by-glenmede-trust-co-na/1950122.html.

Acadia Healthcare Profile

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.

Institutional Ownership by Quarter for Acadia Healthcare (NASDAQ:ACHC)

Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.